Latest news with #DCATWeek2025
Korea Herald
26-05-2025
- Business
- Korea Herald
Samsung Biologics hits W3tr in cumulative orders this year
Samsung Biologics, the biotech arm of Samsung Group, reported Monday that it has surpassed 3 trillion won ($2.2 billion) in cumulative contract orders for 2025, just five months into the year, following a series of major deals with global pharmaceutical firms. According to a regulatory filing, the company recently signed two new contract manufacturing organization, or CMO, deals totaling 440.5 billion won with pharmaceutical companies based in Europe and Asia. These contracts run through December 2030 and December 2033, respectively. Due to non-disclosure agreements, client names and product details were not disclosed. So far in 2025, Samsung Biologics has signed four CMO deals across the US, Europe and Asia. This achievement represents over 60 percent of its total contract value for 2024, reinforcing the company's global competitiveness. The company now counts 17 of the world's top 20 pharmaceutical companies as clients and has accumulated total orders of approximately $18.2 billion since its founding. With the recent launch of its fifth plant in April, adding 180,000 liters of capacity, Samsung Biologics has expanded its total capacity to 784,000 liters, the largest in the world. Samsung Biologics also maintains strong performance in quality control, recording a 99 percent batch success rate last year and securing 356 manufacturing approvals from global regulators as of April 2025. To expand its global presence, the company has actively participated in major industry events including JPMorgan Healthcare Conference, DCAT Week 2025 and PEGS Boston. Samsung Biologics will next join the BIO International Convention held in Boston this June to further strengthen its global partnerships.
Korea Herald
10-03-2025
- Business
- Korea Herald
Samsung Biologics to enhance global ties at DCAT Week 2025
Samsung Biologics, the biotech arm of Samsung Group, said Monday that it will participate in DCAT Week 2025, taking place March 17-20 in New York, as part of its efforts to expand its global business network. Organized annually by the Drug, Chemical & Associated Technologies Association, the event has a history of over 130 years and is a premier networking platform for the global pharmaceutical and biotech industries. Samsung Biologics has participated in DCAT Week every year since 2016, except in 2020, when the event was canceled due to COVID-19. This year, the company will host over 50 business meetings with global pharmaceutical firms at its dedicated meeting space. CEO John Rim will attend for the third consecutive year, engaging with industry leaders to expand strategic partnerships and highlight Samsung Biologics' competitive strengths. The company aims to accelerate its global expansion by securing new contracts and attracting potential clients. Additionally, on March 20, Samsung Biologics will sponsor DCAT Week's main gala dinner, alongside major contract manufacturing firms Lonza and Thermo Fisher Scientific, providing networking opportunities with over 2,500 industry executives. The company also plans to attend the Festival of Biologics USA in April and the PEGS Boston Summit in May to further strengthen its global business network.
